Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study

被引：112

作者：

Burger, R. A.

Brady, M. F.

Bookman, M. A.

Walker, J. L.

Homesley, H. D.

Fowler, J.

Monk, B. J.

Greer, B. E.

Boente, M.

Liang, S. X.

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[2] New York State Dept Hlth, Roswell Pk Mem Inst, Gynecol Oncol Grp, Buffalo, NY 14263 USA

[3] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA

[4] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[5] Brody Sch Med, Greenville, NC USA

[6] Ohio State Univ, James Canc Hosp, Hilliard, OH USA

[7] Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92668 USA

[8] Canc Care Alliance, Seattle, WA USA

[9] Minnesota Oncol & Hematol, Minneapolis, MN USA

[10] SUNY Stony Brook, Stony Brook, NY 11794 USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.18_suppl.lba1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1

引用

页数：1